Statin and PCSK9 Inhibitor Combination for Atherosclerosis Regression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for atherosclerosis, including statins, often fail to achieve optimal LDL-C lowering and may not adequately reduce the progression of coronary atherosclerosis, particularly in statin-intolerant patients or those with high residual risk, necessitating additional therapeutic approaches.
Innovation Solution
Combining a non-PCSK9 LDL-C lowering therapy, such as statins, with a PCSK9 inhibitor, like evolocumab, to achieve significantly lower LDL-C levels and regress coronary atherosclerosis, even in patients who cannot tolerate full statin doses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If statin monotherapy is used to lower LDL-C levels, then LDL-C levels are reduced to some extent, but optimal LDL-C lowering targets are not achieved and atherosclerosis progression is not adequately reduced
Solution Approach 1:
The patent combines statin therapy with PCSK9 inhibitor therapy in a dual treatment regimen. This merging of two different therapeutic mechanisms (HMG-CoA reductase inhibition by statins and PCSK9 pathway inhibition by monoclonal antibodies) produces synergistic LDL-C lowering effects that exceed the sum of individual therapies, thereby achieving both optimal LDL-C reduction and adequate atherosclerosis regression
2Quantity of substance
If higher doses of statins are administered to achieve greater LDL-C lowering, then LDL-C levels decrease further, but statin intolerance limits the ability to use full therapeutic doses
Solution Approach 1:
The PCSK9 inhibitor acts as an intermediary mechanism that achieves LDL-C lowering through a different biochemical pathway (PCSK9-proteasome-LDL receptor axis) rather than HMG-CoA reductase inhibition. This allows patients who cannot tolerate full-dose statins to achieve equivalent or superior LDL-C reduction through the PCSK9 inhibitor pathway, bypassing the tolerance limitation
3Quantity of substance
If combination therapy with statin and PCSK9 inhibitor is used, then LDL-C levels are lowered to below 60 mg/dL and atherosclerosis regresses, but treatment complexity increases
Solution Approach 1:
The treatment regimen is segmented into distinct phases: initial statin therapy to establish baseline LDL-C reduction, followed by addition of PCSK9 inhibitor to achieve target LDL-C <60 mg/dL, and maintenance phase with optimized dual therapy. This segmentation allows systematic management of the combination therapy, making the complex regimen more manageable and monitorable
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This combination therapy effectively lowers LDL-C levels to below 60 mg/dL, reduces atheroma volume, and decreases the risk of cardiovascular events by up to 10%, providing incremental benefits over statin monotherapy in reducing atherosclerosis progression and improving cardiovascular outcomes.
Implementation Method 1
administering an anti-PCSK9 neutralizing antibody to the subject
Data Source
AI summary
Provided herein are combinations of therapies that provide for the treatment, including regression, of atherosclerosis and/or improvement of cardiovascular outcomes. Generally described, this includes a first, non-PCSK9 LDL-C lowering agent (such as a statin or other non-PCSK9 LDL-C lowering therapy), combined with a second, PCSK9 inhibitor therapy (such as a PCSK9 antibody or anti-RNA). The application of both therapies, at adequately elevated levels so as to reduce the LDL-C level of the subject to very low levels, for an adequate period of time, has been determined to provide an added benefit of further protection from atherosclerosis and improve a subject's cardiovascular outcomes.